An established Alacrita client building a business in the inhaled therapeutics sector asked us to carry out a technical and commercial due diligence of two development stage companies based in the US. Both companies made available datarooms containing their core documentation and also provided access to their management teams for Q&A.
Alacrita assembled a respiratory DD team that had worked on a previous transaction comprising clinical, regulatory, manufacturing/supply chain and commercial expertise. The team conducted a thorough risk analysis of both companies that covered a total of six development stage assets ranging from anti-infectives through to CNS-acting drugs. A number of red flags were raised for one of the target companies and no viable mitigation strategies could be identified. The other company, however, was assessed as a more attractive and less risky proposition and Alacrita's client proceeded with the transaction.
Due Diligence Services
Alacrita's due diligence experts have conducted over 200 major assignments for large pharma, biotech, universities and investors, underpinned by our ability to ensure each due diligence exercise is supported by individuals with the precise expertise required for a complete, thorough and accurate assessment.Back